Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study.
A pilot study was performed to determine the effect of 40,000 IU Epo on myocardial damage in 51 patients with non-ST segment elevation acute coronary syndrome (non-STE ACS). No significant difference in myocardial damage was found, but an increased systolic blood pressure was noticed.
Liem
Anho
A
Oosterschelde Ziekenhuizen, Goes, The Netherlands. anho@zeelandnet.nl
van de Woestijne
Anton P
AP
Bruijns
Erik
E
Roeters van Lennep
Henk W O
HW
de Boo
Job A J
JA
van Halteren
Henk K
HK
van Es
Teun P
TP
Jukema
J Wouter
JW
van der Laarse
Arnoud
A
Zwinderman
Aeilko H
AH
van Veldhuisen
Dirk J
DJ
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000473:pathology*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D010865:Pilot Projects; D011446:Prospective Studies; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa